Correlation Between AN2 Therapeutics and Puma Biotechnology

Can any of the company-specific risk be diversified away by investing in both AN2 Therapeutics and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AN2 Therapeutics and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AN2 Therapeutics and Puma Biotechnology, you can compare the effects of market volatilities on AN2 Therapeutics and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AN2 Therapeutics with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of AN2 Therapeutics and Puma Biotechnology.

Diversification Opportunities for AN2 Therapeutics and Puma Biotechnology

0.51

Correlation Coefficient

AN2 Therapeutics  Puma Biotechnology

Very weak diversification

The 3 months correlation between AN2 and Puma is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding AN2 Therapeutics and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and AN2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AN2 Therapeutics are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of AN2 Therapeutics i.e., AN2 Therapeutics and Puma Biotechnology go up and down completely randomly.

Pair Corralation between AN2 Therapeutics and Puma Biotechnology

Given the investment horizon of 90 days AN2 Therapeutics is expected to generate 0.58 times more return on investment than Puma Biotechnology. However, AN2 Therapeutics is 1.73 times less risky than Puma Biotechnology. It trades about 0.07 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.03 per unit of risk. If you would invest  138.00  in AN2 Therapeutics on December 26, 2024 and sell it today you would earn a total of  13.00  from holding AN2 Therapeutics or generate 9.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

AN2 Therapeutics  vs.  Puma Biotechnology

AN2 Therapeutics

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, AN2 Therapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Puma Biotechnology

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with AN2 Therapeutics and Puma Biotechnology

The main advantage of trading using opposite AN2 Therapeutics and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AN2 Therapeutics position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.

The idea behind AN2 Therapeutics and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.